The scale of China's CDMO market will move from tens of billions to hundreds of billions, and the head has increased its layout

"There are thousands of biotech companies in China, and the demand for biomedical production in the future is considerable, and we are optimistic about the growth space
of the domestic CDMO market.
" The president of Thermo Fisher Fisher Scientific China recently told the media at the Expo, which shows that it is full of confidence
in China's CDMO market.
Leading companies are actively expanding production Not only multinational pharmaceutical companies, from the public news since the beginning of 2022, domestic CDMO companies, especially head enterprises, have been actively expanding their production layout
since this year.
For example, on November 15, Jiuzhou Pharmaceutical issued an announcement that the application for non-public offering of shares was approved by the Issuance Review Committee of the China Securities Regulatory Commission, and the company's application for non-public offering of shares was approved
.
According to the fixed increase plan disclosed by the company on August 5, the total amount of funds to be raised by the issuing company will not exceed 2.
5 billion yuan, and the funds raised will be used for the construction project (phase I project) of innovative drug CDMO (contract R&D and production organization) production base of Ribo (Taizhou) Pharmaceutical Co.
, Ltd.
, the CDMO construction project of API of Ribo (Suzhou) Pharmaceutical Co.
, Ltd.
, and supplementary working capital
.
BOTN announced on October 12 that in order to promote the development of the company's gene cell therapy CDMO business, it agreed to conduct a series B financing of Suzhou BOTN, a holding subsidiary, with a financing amount of 520 million yuan
.
Earlier, in February, the company announced an investment of 260 million yuan to expand the production capacity
of API CDMO at the Chongqing Changshou production base.
Huashen Technology announced on September 30 that its wholly-owned subsidiary, Hainan Huashen Xingrui Pharmaceutical Technology Co.
, Ltd.
, increased its capital to Shanghai Lingkai Pharmaceutical Technology Co.
, Ltd.
with its own funds of no more than 200 million yuan, which is also another cooperation after the company invested in Shandong Lingkai and officially entered the CDMO industry, which will help consolidate the company's industrial development foundation
in the CDMO industry 。 Haixiang Pharmaceutical announced on September 26 that in order to further enhance the company's comprehensive R&D strength and expand the CDMO rapid response capability and the scale of animal protection sector business, the company intends to purchase about 45 mu of industrial land through its subsidiary (the specific area is subject to the actual area of the land transfer contract) to invest in the construction of the headquarters research institute project, so as to expand the CDMO service capacity, improve efficiency, help CDMO project development, and enhance R&D strength
。 Also in September, Kaileying disclosed that the company plans to invest 4-5 billion yuan in the biomedical R&D and production integrated base project in Taixing, Jiangsu Province, the project construction content is the research and development and production of small molecule CDMO chemical raw materials and APIs, and the local area will also reserve sufficient land for the future expansion of small molecule CDMO pharmaceutical preparations, drug research and development, new technology promotion and application and other project construction
.
The industry believes that behind the head CDMO companies have increased their layout and expanded production, it is a signal
that the head CDMO companies are full of orders and strong demand.
China's CDMO market size will enter 100 billion In recent years, under the background of the vigorous development of the innovative drug industry and the high cost of new drug research and development, China's CDMO industry has ushered in rapid growth, and the market scale has continued to expand
.
According to the data in the "CDMO Market Development Status and Future Trend Research Report" released by Frost & Sullivan, the size of China's CDMO market has increased from 13.
2 billion yuan in 2017 to 47.
3 billion yuan in 2021, with a compound annual growth rate of 37.
7%, and is expected to reach 157.
1 billion yuan by 2025 and 355.
9 billion yuan
in 2030.
From tens of billions to hundreds of billions, it can be seen that China's CDMO market space is vast in the future, and in this context, enterprises on the track, especially the head enterprises with advantages, are expected to usher in opportunities
.
From the third quarter report of 2022, many leading CDMO companies have achieved outstanding results, such as Kailaiying, which achieved double growth in revenue and net profit in the first three quarters, achieving a total operating income of 7.
812 billion yuan, an increase of 167.
25% year-on-year; The net profit attributable to the parent was 2.
721 billion yuan, an increase of 291.
58%
year-on-year.
BOTN also received a satisfactory "report card", achieving main revenue of 5.
218 billion yuan in the first three quarters, up 157.
05% year-on-year; The net profit attributable to the parent was 1.
578 billion yuan, an increase of 337.
42%
year-on-year.
Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.